Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

Two Kovsie women involved in international sports events
2012-05-14

 

Hetsie Veitch and Ebeth Grobbelaar
Photo: René-Jean van der Berg
14 May 2012

The organisers of two international sports events will depend on the expertise of two Kovsie women to make the events a major success.

The honour to be involved in international sports event has befallen Ms Hetsie Veitch and Ms Ebeth Grobbelaar.

The honour is the result of many years’ hard work and devotion in their respective fields.

In June, when the USA chooses the team to represent it at the 2012 Paralympic Games in London, Ms Veitch will be one of the classifiers who will determine in which categories athletes may compete.

Ms Veitch, Head of the Unit for Students with Disabilities at the University of the Free State (UFS), has been invited to be a member of the Classification Panel at the final USA Paralympic athletics trials. The trials take place from 27 June to 1 July 2012 in Indianapolis, Indiana, in the USA.

Ms Veitch and four other classifiers, two from Brazil, one from Canada and one from the USA, will test and verify the international classification status of the American athletes. No athlete will be allowed to take part without their classification being verified by the panel.

Ms Veitch, who recently achieved the status of International Paralympic Committee (IPC) Athletics Classifier, the highest achievement for a classifier in sport for the disabled, said that this category of sport has always been her passion.

“To have the opportunity to be involved in the classification of the USA team for the London 2012 Paralympic Games is a huge honour. I am going to start working on being chosen for the official IPC classification panel for the 2016 Paralympic Games in Brazil.”

Ms Grobbelaar, Assistant Director of the South African Testing Laboratory for Prohibited Substances at the UFS, was invited to be involved in the Drugs Control Centre in the unit against prohibited substances which will test sportsmen and women during this year’s Olympic Games in London.

Ms Grobbelaar said that even though the future of sportsmen and women would be in her hands, she is totally capable of carrying out the task that awaits her.

“I will be part of the laboratory team who will test the athletes’ samples for prohibited substances. I was part of the South African team who tested samples in our own laboratory in 2010 during the FIFA Soccer World Cup, as well as for the All Africa Games. The task is one I perform every day in our own laboratories. Each sample that I analyse determines an athlete’s future. The circumstances during the Olympic Games are different, but the work remains the same.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept